Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has initiated a second development program with R-107, the ...
SAN FRANCISCO and TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into a Strategic Collaboration Agreement (the C...
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that compelling data demonstrating that nitric oxide achieved viral clearance i...
SAN FRANCISCO and TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Company will focus its resources primarily on de...
SAN FRANCISCO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that its shares will resume trading today on the TSX VENTURE EXCHANGE (“TSXV”). The Company a...
SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announced today that Kost Forer Gabbay & Kasierer/Ernst & Young Global (“E&Y”) have, at the request of the Company, resi...
SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today provided the following updates regarding recent and ongoing activities. Private Placement As previously announced on July 24, 2020,...
SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announced today that on and effective July 22, 2020 it has closed in escrow its previously announced non-brokered private placement (the “...
SAN FRANCISCO, July 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that it has entered into a License Agreement (the “License Agreement” ) with Salzman Group, Inc. ( “Salzman ...
SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announces that it has received conditional approval from the TSX Venture Exchange ( " TSXV ”) and partial revocation orders from the Briti...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...